Curated News
By: NewsRamp Editorial Staff
June 02, 2026
Optimi Health Produces GMP Psilocybin Capsules for Global Trials
TLDR
- Optimi Health's GMP production run of 5mg psilocybin capsules positions it to supply regulated markets, gaining first-mover advantage.
- Optimi completed all stages of GMP production in-house, from biomass cultivation to encapsulation, ensuring quality and scalability.
- Optimi's psilocybin capsules, already prescribed in Australia, offer new hope for treatment-resistant depression patients.
- Optimi Health's psilocybin capsules are being manufactured for clinical trials in the US and Europe.
Impact - Why it Matters
This news matters because it marks a significant step toward making regulated psilocybin therapies more accessible for patients suffering from treatment-resistant depression and other mental health conditions. Optimi's GMP-certified production of 5mg psilocybin capsules ensures consistent quality and safety, which is critical for clinical research and patient access. With ongoing clinical trials in the U.S. and Europe, this development could accelerate the approval and availability of psychedelic-assisted therapies, offering new hope for individuals who have not responded to traditional treatments. Additionally, Optimi's vertical integration from cultivation to packaging demonstrates a scalable model that could reduce costs and improve supply chain reliability, potentially making these therapies more affordable and widely available in the future.
Summary
Optimi Health Completes GMP Production of 5mg Psilocybin Capsules for Global Clinical Trials and Patient Access
Optimi Health (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, has announced the successful completion of a GMP production run of its 5mg psilocybin finished drug product. These capsules utilize the same formulation currently prescribed to patients in Australia for treatment-resistant depression, with additional product from the run designated for upcoming clinical research in the United States and clinical trials in Europe. The company emphasized that all stages of manufacturing—including biomass cultivation, active pharmaceutical ingredient extraction, encapsulation, and packaging—were completed in-house at its Health Canada-licensed facility. This vertically integrated platform and commercial-scale production capacity position Optimi to supply finished psilocybin and MDMA drug products to regulated markets internationally for both patient access programs and clinical research initiatives.
Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) is a commercial-stage pharmaceutical company focused on manufacturing and distributing GMP-grade psychedelic drug products for mental health therapies. As a Health Canada-licensed pharmaceutical manufacturer, Optimi produces validated MDMA and botanical psilocybin drug products at its GMP-compliant facilities in British Columbia, Canada. The company supplies both active pharmaceutical ingredients and finished dosage forms to regulated clinical and therapeutic programs internationally, with products currently prescribed to patients in Australia under the country’s Authorized Prescriber Scheme and accessible in Canada through the Special Access Program. For more information, visit optimi.net.
This news was disseminated by BioMedWire (“BMW”), a specialized communications platform focusing on the latest developments in the Biotechnology, Biomedical Sciences, and Life Sciences sectors. BMW is part of the Dynamic Brand Portfolio @ IBN, which provides access to a vast network of wire solutions and tailored corporate communications solutions. The full press release is available at https://ibn.fm/Rx3ky.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Optimi Health Produces GMP Psilocybin Capsules for Global Trials
